Biological
Euvichol®
Euvichol® is a biological therapy with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 32 (66.7%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_3
Safety and Immunogenicity of a New Formulation of Euvichol®
NCT02502331
completedphase_3
To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children
NCT02164110
completedphase_1
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men
NCT01707537
Clinical Trials (3)
Showing 3 of 3 trials
NCT02502331Phase 3
Safety and Immunogenicity of a New Formulation of Euvichol®
NCT02164110Phase 3
To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children
NCT01707537Phase 1
To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3